Search - tctmd.com

Displaying 81 - 100 of 533

Sort: Relevancy | Date

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

Nasal Bumetanide Safe, Effective in Healthy Adults

News Conference News AHA 2024

Nasal Bumetanide Safe, Effective in Healthy Adults

Yael L. Maxwell

November 18, 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

News Features

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

November 13, 2024

TCTMD’s Top 10 Most Popular Stories for October 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2024

November 01, 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

October 28, 2024

TCT 625: A Lower Ratio of Regurgitant Volume to Left Atrium Volume Is Associated With a Higher Incidence of Heart Failure Hospitalization in Patients With Ventricular Functional Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair

Presentation TCT 2024

TCT 625: A Lower Ratio of Regurgitant Volume to Left Atrium Volume Is Associated With a Higher Incidence of Heart Failure Hospitalization in Patients With Ventricular Functional Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair

Presenter: Masafumi Yoshikawa

October 28, 2024

What’s Going to Be Big at TCT 2024?

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

News Daily News

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

October 01, 2024

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

News Daily News

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

Michael O'Riordan

September 27, 2024

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

News Daily News

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

September 20, 2024

Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home

News Daily News

Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home

September 16, 2024

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

News Conference News ESC 2024

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

September 01, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

News Conference News ESC 2024

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

August 31, 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

August 31, 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

News Conference News ESC 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

Michael O'Riordan

August 30, 2024

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.